AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results
Conference Call and Webcast on March 12, 2013
REDWOOD CITY, Calif., March 7, 2013
REDWOOD CITY, Calif., March 7, 2013 /PRNewswire/ --AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that it will release fourth
quarter 2012 financial results after market close on Tuesday, March 12, 2013.
AcelRx management will host an investment-community conference call at 4:30
p.m. Eastern time (1:30 p.m. Pacific time) on March 12, 2013 to discuss the
financial results and provide a corporate update.
Investors who wish to participate in the conference call may do so by dialing
(800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers or
(412) 858-4600 for international callers. Those interested in listening to the
conference call live via the Internet may do so by visiting the Investors page
of the company's website at www.acelrx.com and clicking on the webcast link on
the Investor home page.
A webcast replay will be available on the AcelRx website for 90 days following
the call by visiting the Investors page of the company's website at
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate,
the ARX-01 Sufentanil NanoTab PCA System, is designed to solve the problems
associated with post-operative intravenous patient-controlled analgesia which
has been shown to cause harm to patients following surgery because of the side
effects of morphine, the invasive IV route of delivery and the complexity of
infusion pumps. ARX-01 has successfully completed two of its three planned
Phase 3 clinical trials and a New Drug Application submission is planned for
the third quarter of 2013. AcelRx recently completed enrollment in a Phase 2
study for ARX-04, a sufentanil formulation for the treatment of
moderate-to-severe acute pain, funded through a grant from U.S. Army Medical
Research and Materiel Command, and top-line results are expected in the second
quarter of 2013. The company has two additional pain treatment product
candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical
development. For additional information about AcelRx's clinical programs
please visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements, including, but not
limited to, statements related to anticipated timing of completion of AcelRx
Pharmaceuticals' current clinical trials, submission of the NDA, and the
therapeutic potential of AcelRx Pharmaceuticals' product candidates.These
forward-looking statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and uncertainties.
AcelRx Pharmaceuticals' actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without limitation,
risks related to: the success, cost and timing of AcelRx Pharmaceuticals'
product development activities and clinical trials; its ability to obtain
sufficient financing to complete development and registration of its product
candidates in the United States and Europe; its ability to obtain and maintain
regulatory approvals of its product candidates; the market potential for its
product candidates; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx Pharmaceuticals' U.S. Securities and Exchange Commission
filings, including its Current Report on Form 8-K filed with the SEC on
December 7, 2012. AcelRx Pharmaceuticals undertakes no duty or obligation to
update any forward-looking statements contained in this release as a result of
new information, future events or changes in its expectations.
SOURCE AcelRx Pharmaceuticals, Inc.
Contact: Jim Welch, Chief Financial Officer, +1-650-216-3511,
Press spacebar to pause and continue. Press esc to stop.